Historical Valuation
Artelo Biosciences Inc (ARTL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.38. The fair price of Artelo Biosciences Inc (ARTL) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.60
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Artelo Biosciences Inc (ARTL) has a current Price-to-Book (P/B) ratio of -3.12. Compared to its 3-year average P/B ratio of -0.16 , the current P/B ratio is approximately 1886.05% higher. Relative to its 5-year average P/B ratio of 0.42, the current P/B ratio is about -834.92% higher. Artelo Biosciences Inc (ARTL) has a Forward Free Cash Flow (FCF) yield of approximately -318.90%. Compared to its 3-year average FCF yield of -178.52%, the current FCF yield is approximately 78.64% lower. Relative to its 5-year average FCF yield of -125.42% , the current FCF yield is about 154.26% lower.
P/B
Median3y
-0.16
Median5y
0.42
FCF Yield
Median3y
-178.52
Median5y
-125.42
Competitors Valuation Multiple
AI Analysis for ARTL
The average P/S ratio for ARTL competitors is 0.00, providing a benchmark for relative valuation. Artelo Biosciences Inc Corp (ARTL.O) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ARTL
1Y
3Y
5Y
Market capitalization of ARTL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ARTL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ARTL currently overvalued or undervalued?
Artelo Biosciences Inc (ARTL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.38. The fair price of Artelo Biosciences Inc (ARTL) is between to according to relative valuation methord.
What is Artelo Biosciences Inc (ARTL) fair value?
ARTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Artelo Biosciences Inc (ARTL) is between to according to relative valuation methord.
How does ARTL's valuation metrics compare to the industry average?
The average P/S ratio for ARTL's competitors is 0.00, providing a benchmark for relative valuation. Artelo Biosciences Inc Corp (ARTL) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Artelo Biosciences Inc (ARTL) as of Jan 09 2026?
As of Jan 09 2026, Artelo Biosciences Inc (ARTL) has a P/B ratio of -3.12. This indicates that the market values ARTL at -3.12 times its book value.
What is the current FCF Yield for Artelo Biosciences Inc (ARTL) as of Jan 09 2026?
As of Jan 09 2026, Artelo Biosciences Inc (ARTL) has a FCF Yield of -318.90%. This means that for every dollar of Artelo Biosciences Inc’s market capitalization, the company generates -318.90 cents in free cash flow.
What is the current Forward P/E ratio for Artelo Biosciences Inc (ARTL) as of Jan 09 2026?
As of Jan 09 2026, Artelo Biosciences Inc (ARTL) has a Forward P/E ratio of -0.23. This means the market is willing to pay $-0.23 for every dollar of Artelo Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Artelo Biosciences Inc (ARTL) as of Jan 09 2026?
As of Jan 09 2026, Artelo Biosciences Inc (ARTL) has a Forward P/S ratio of 0.00. This means the market is valuing ARTL at $0.00 for every dollar of expected revenue over the next 12 months.